

Novavax COVID-19 Vaccine

(FDA Emergency Use Authorization)

The Centers for Disease Control and Prevention (CDC) approved the Advisory Committee on Immunization Practices (ACIP) recommendation for the NOVAVAX COVID-19 vaccine.

Key Considerations to Note

- Emergency Use Authorization (EUA) has been granted for those 12 years of age and up as a primary two-dose series and as an updated vaccine for those who have previously been vaccinated.
- Novavax COVID-19 is a protein subunit vaccine; it contains harmless proteins of the COVID virus with an adjuvant that helps the body's immune system respond to the virus in the future.
- This mechanism of action has been used for more than 30 years in other vaccines including those for hepatitis B, the flu and whooping cough.
- The vaccine does NOT contain eggs, preservatives, latex or metals.
- The recommended dosing includes:
 - Two doses in the primary series, administered as an intramuscular injection in the upper arm.
 - The second dose is given 3 weeks after the first dose.
 - Immunocompromised individuals may receive extra doses, based upon health care provider recommendation.
 - People aged 12 years and older choosing to use Novavax who have had previous COVID vaccination may get one updated Novavax COVID-19 vaccine.

Scan for the most current information.



Novavax COVID-19
Vaccine, Adjuvanted
| FDA